These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 20357249)

  • 1. CXC chemokine ligand 2 induced by receptor activator of NF-kappa B ligand enhances osteoclastogenesis.
    Ha J; Choi HS; Lee Y; Kwon HJ; Song YW; Kim HH
    J Immunol; 2010 May; 184(9):4717-24. PubMed ID: 20357249
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of RANKL-induced osteoclastogenesis by (-)-DHMEQ, a novel NF-kappaB inhibitor, through downregulation of NFATc1.
    Takatsuna H; Asagiri M; Kubota T; Oka K; Osada T; Sugiyama C; Saito H; Aoki K; Ohya K; Takayanagi H; Umezawa K
    J Bone Miner Res; 2005 Apr; 20(4):653-62. PubMed ID: 15765185
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CXCL2 mediates lipopolysaccharide-induced osteoclastogenesis in RANKL-primed precursors.
    Ha J; Lee Y; Kim HH
    Cytokine; 2011 Jul; 55(1):48-55. PubMed ID: 21507677
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phosphatidylserine-containing liposomes inhibit the differentiation of osteoclasts and trabecular bone loss.
    Wu Z; Ma HM; Kukita T; Nakanishi Y; Nakanishi H
    J Immunol; 2010 Mar; 184(6):3191-201. PubMed ID: 20176740
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CCR1 chemokines promote the chemotactic recruitment, RANKL development, and motility of osteoclasts and are induced by inflammatory cytokines in osteoblasts.
    Yu X; Huang Y; Collin-Osdoby P; Osdoby P
    J Bone Miner Res; 2004 Dec; 19(12):2065-77. PubMed ID: 15537451
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stromal cell-derived factor-1 (SDF-1) recruits osteoclast precursors by inducing chemotaxis, matrix metalloproteinase-9 (MMP-9) activity, and collagen transmigration.
    Yu X; Huang Y; Collin-Osdoby P; Osdoby P
    J Bone Miner Res; 2003 Aug; 18(8):1404-18. PubMed ID: 12929930
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epigallocatechin-3-gallate inhibits osteoclastogenesis by down-regulating c-Fos expression and suppressing the nuclear factor-kappaB signal.
    Lee JH; Jin H; Shim HE; Kim HN; Ha H; Lee ZH
    Mol Pharmacol; 2010 Jan; 77(1):17-25. PubMed ID: 19828731
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selective inhibition of NF-kappa B blocks osteoclastogenesis and prevents inflammatory bone destruction in vivo.
    Jimi E; Aoki K; Saito H; D'Acquisto F; May MJ; Nakamura I; Sudo T; Kojima T; Okamoto F; Fukushima H; Okabe K; Ohya K; Ghosh S
    Nat Med; 2004 Jun; 10(6):617-24. PubMed ID: 15156202
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of osteoclast differentiation and bone resorption by sauchinone.
    Han KY; Yang D; Chang EJ; Lee Y; Huang H; Sung SH; Lee ZH; Kim YC; Kim HH
    Biochem Pharmacol; 2007 Sep; 74(6):911-23. PubMed ID: 17662251
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Caffeic acid phenethyl ester inhibits osteoclastogenesis by suppressing NF kappaB and downregulating NFATc1 and c-Fos.
    Ha J; Choi HS; Lee Y; Lee ZH; Kim HH
    Int Immunopharmacol; 2009 Jun; 9(6):774-80. PubMed ID: 19285574
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 12-O-tetradecanoylphorbol-13-acetate (TPA) inhibits osteoclastogenesis by suppressing RANKL-induced NF-kappaB activation.
    Wang C; Steer JH; Joyce DA; Yip KH; Zheng MH; Xu J
    J Bone Miner Res; 2003 Dec; 18(12):2159-68. PubMed ID: 14672351
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antioxidant alpha-lipoic acid inhibits osteoclast differentiation by reducing nuclear factor-kappaB DNA binding and prevents in vivo bone resorption induced by receptor activator of nuclear factor-kappaB ligand and tumor necrosis factor-alpha.
    Kim HJ; Chang EJ; Kim HM; Lee SB; Kim HD; Su Kim G; Kim HH
    Free Radic Biol Med; 2006 May; 40(9):1483-93. PubMed ID: 16632109
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NF-kappaB inhibitor dehydroxymethylepoxyquinomicin suppresses osteoclastogenesis and expression of NFATc1 in mouse arthritis without affecting expression of RANKL, osteoprotegerin or macrophage colony-stimulating factor.
    Kubota T; Hoshino M; Aoki K; Ohya K; Komano Y; Nanki T; Miyasaka N; Umezawa K
    Arthritis Res Ther; 2007; 9(5):R97. PubMed ID: 17892600
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RANK is the essential signaling receptor for osteoclast differentiation factor in osteoclastogenesis.
    Nakagawa N; Kinosaki M; Yamaguchi K; Shima N; Yasuda H; Yano K; Morinaga T; Higashio K
    Biochem Biophys Res Commun; 1998 Dec; 253(2):395-400. PubMed ID: 9878548
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Erythromycin inhibits wear debris-induced osteoclastogenesis by modulation of murine macrophage NF-kappaB activity.
    Ren W; Li XH; Chen BD; Wooley PH
    J Orthop Res; 2004 Jan; 22(1):21-9. PubMed ID: 14656655
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TRAF2 is essential for TNF-alpha-induced osteoclastogenesis.
    Kanazawa K; Kudo A
    J Bone Miner Res; 2005 May; 20(5):840-7. PubMed ID: 15824857
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epidermal growth factor receptor regulates osteoclast differentiation and survival through cross-talking with RANK signaling.
    Yi T; Lee HL; Cha JH; Ko SI; Kim HJ; Shin HI; Woo KM; Ryoo HM; Kim GS; Baek JH
    J Cell Physiol; 2008 Nov; 217(2):409-22. PubMed ID: 18543257
    [TBL] [Abstract][Full Text] [Related]  

  • 18. T-cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-gamma.
    Takayanagi H; Ogasawara K; Hida S; Chiba T; Murata S; Sato K; Takaoka A; Yokochi T; Oda H; Tanaka K; Nakamura K; Taniguchi T
    Nature; 2000 Nov; 408(6812):600-5. PubMed ID: 11117749
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The antirheumatic drug leflunomide inhibits osteoclastogenesis by interfering with receptor activator of NF-kappa B ligand-stimulated induction of nuclear factor of activated T cells c1.
    Urushibara M; Takayanagi H; Koga T; Kim S; Isobe M; Morishita Y; Nakagawa T; Löeffler M; Kodama T; Kurosawa H; Taniguchi T
    Arthritis Rheum; 2004 Mar; 50(3):794-804. PubMed ID: 15022321
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sesquiterpene lactone parthenolide blocks lipopolysaccharide-induced osteolysis through the suppression of NF-kappaB activity.
    Yip KH; Zheng MH; Feng HT; Steer JH; Joyce DA; Xu J
    J Bone Miner Res; 2004 Nov; 19(11):1905-16. PubMed ID: 15476591
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.